Progress against malignant brain tumors depends on team science: shared biobanks and registries, multi-disciplinary clinical trials, and partnerships across neurosurgery, neuro-oncology, pathology, and engineering. The MLiNS lab contributes to this ecosystem through translational studies that combine prospective trial design, rich tumor biology, and rigorous data science, including work on privacy-preserving collaboration (for example, federated learning across sites) so institutions can learn together without centralizing sensitive patient data. The publications below highlight representative collaborative neuro-oncology efforts.
A multi-institutional spatial analysis characterizing where IDH-mutant gliomas arise in the brain, informing surgical planning, sampling, and interpretation of tumor biology across centers.
Supervised machine learning models predict clinical trial enrollment for adults with low- and high-grade glioma from routine data, with the goal of improving accrual and matching patients to studies.
Paired stimulated Raman histology and fluorescence microscopy map protoporphyrin IX (PpIX) during glioma resection, linking 5-ALA fluorescence to tissue context for more interpretable intraoperative guidance.
A phase 1, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy delivered to the resection cavity in adults with primary high-grade glioma, reporting safety and early efficacy signals.
Spatiotemporal profiling of glioma heterogeneity implicates COL1A1 in the tumor microenvironment as a tractable target to slow progression, connecting matrix biology to therapeutic opportunity. The MLiNS lab contributed a semantic segmentation model to detect oncostreams in brain tumor microscopy images, supporting quantitative analysis of tumor architecture.
A practical overview of federated learning for multi-site clinical research in neurosurgery: how models can be trained collaboratively without centralizing raw patient data, and what that means for governance and discovery.